基因对心血管药物代谢影响的临床意义。

Clinical significance of genetic influences on cardiovascular drug metabolism.

作者信息

Arcavi L, Benowitz N L

机构信息

Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center, CA 94110.

出版信息

Cardiovasc Drugs Ther. 1993 Jun;7(3):311-24. doi: 10.1007/BF00880154.

DOI:10.1007/BF00880154

PMID:8103355

Abstract

Inherited differences in metabolism may be responsible for individual variability in the efficacy of drugs and the occurrence of adverse drug reactions. Among the cardiovascular drugs reported to exhibit genetic polymorphism are debrisoquine, sparteine, some beta-adrenoceptor antagonists, flecainide, encainide, propafenone, nifedipine, procainamide, and hydralazine. The implications of genetic differences in the metabolism of these drugs for cardiovascular therapeutics is the subject of this review.

摘要

代谢方面的遗传差异可能是药物疗效个体差异以及药物不良反应发生的原因。据报道，表现出遗传多态性的心血管药物包括异喹胍、金雀花碱、一些β肾上腺素受体拮抗剂、氟卡尼、恩卡尼、普罗帕酮、硝苯地平、普鲁卡因胺和肼屈嗪。这些药物代谢中的遗传差异对心血管治疗的影响是本综述的主题。